Search Results for:
-
Collaborations Between Biotech And Pharmaceutical Companies: July 1 - August 25, 2011
protease inhibitor TMC435 in a Phase II study in chronic hepatitis C virus Financial terms were not disclosed (7/7) Rib-X Pharmaceuticals Inc. (New Haven, Conn.) Sanofi SA (Paris) $763 Exclusive worldwide research collaboration and licensing option for antibiotics resulting from its RX-04 program to treat resistant Gram-positive and resistant Gram-negative pathogens Rib-X will receive $10M in an up-front payment and is eligible to receive up to an additional $9M in near-term research -
Non-U.S. Clinical Trials & Regulatory Actions: July 2011
protease inhibitor Hepatitis C virus CHMP recommended approval of Incivo in combination with pegylated interferon and ribavirin (7/25) MISCELLANEOUS Amsterdam Molecular Therapeutics NV (Amsterdam, the Netherlands) Glybera Alipogene tiparvovec -
No-Strings Deals Let Rivals Combine Unapproved Drugs
In a Phase II trial of protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052, six of 11 patients broke through, but the others achieved a cure -
ChronTech Pharma Raising Cash, Beefing Up Board
Notwithstanding the recent launch of two protease inhibitors, Incivek (telaprevir) and Victrelis (boceprevir), marketed, respectively, by Vertex Pharmaceuticals Inc., of Cambridge, Mass., and by Merck & Co., Inc., of Whitehouse Station, N.J., Vahlne sees plenty of room in that market for additional products...The protease inhibitors that are on the market today have severe side effects, anemia, for one," he said -
Other News To Note
Tibotec Virco-Virology BVBA, of Beerse, Belgium, part of Johnson & Johnson's Janssen Pharmaceutical unit, said the European Committee for Medicinal Products for Human Use recommended approval of protease inhibitor Incivo (telaprevir) in combination with pegylated interferon and ribavirin in chronic genotype-1 hepatitis C virus -
Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: June 1 - July 22, 2011
Inc. (Whitehouse Station, N.J.) Roche AG (Basel, Switzerland) ND Nonexclusive deal for the global promotion of protease inhibitor Victrelis as part of a triple combination therapy regimen with peginterferon alfa and ribavirin The firms previously disclosed an agreement to promote Victrelis in the U.S., where it gained marketing approval this year (7/21) Victory Pharma Inc. (San Diego) Shionogi Inc. (Florham Park, N.J.) $127 Agreement for Shionogi to acquire all currently marketed -
Collaborations Between Biotech And Pharmaceutical Companies: June 1 - July 22, 2011
protease inhibitor TMC435 in a Phase II study in chronic hepatitis C virus Financial terms were not disclosed (7/7) Rib-X Pharmaceuticals Inc. (New Haven, Conn.) Sanofi SA (Paris) $763 Exclusive worldwide research collaboration and licensing option for antibiotics resulting from its RX-04 program to treat resistant Gram-positive and resistant Gram-negative pathogens Rib-X will receive $10M in an up-front payment and is eligible to receive up to an additional $9M in near-term research -
Other News To Note
Inc., of Whitehouse Station, N.J., and Roche AG, of Basel, Switzerland, inked a nonexclusive deal for the global promotion of protease inhibitor Victrelis (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin -
Bench Press
But two anti-HIV drug classes, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, are synergistic despite the fact that they bind to different proteins -
Early Stage Deals Still Wow? Innate Jumps on BMS Alliance
followed its recent approval of hepatitis C virus protease inhibitor Incivek (telaprevir) by paying $60 million up front for worldwide rights to preclinical nucleotide analogues ALS-2200 and ALS-2158 from Alios BioPharma Inc., of South San Francisco -
Early Stage Deals Still Wow? Innate Jumps on BMS Alliance
followed its recent approval of hepatitis C virus protease inhibitor Incivek (telaprevir) by paying $60 million up front for worldwide rights to preclinical nucleotide analogues ALS-2200 and ALS-2158 from Alios BioPharma Inc., of South San Francisco -
Early Stage Deals Still Wow? Innate Jumps on BMS Alliance
followed its recent approval of hepatitis C virus protease inhibitor Incivek (telaprevir) by paying $60 million up front for worldwide rights to preclinical nucleotide analogues ALS-2200 and ALS-2158 from Alios BioPharma Inc., of South San Francisco -
Other News To Note
Pharmasset Inc., of Princeton, N.J., inked a collaboration with Johnson & Johnson unit Tibotec Pharmaceuticals Inc., of Raritan, N.J., to evaluate its nucleotide polymerase inhibitor PSI-7977 in combination with Tibotec's protease inhibitor TMC435 in a Phase II study in chronic hepatitis C virus (HCV -
Other News To Note
Gilead Sciences Inc., of Foster City, Calif., entered a license agreement with New Brunswick, N.J.-based Johnson & Johnson subsidiary Tibotec Pharmaceuticals to develop and commercialize a fixed-dose combination of Gilead's Phase III boosting agent cobicistat and Tibotec's FDA-approved protease inhibitor Prezista (darunavir) for HIV -
Commercial Era for Biotech? Plan Early, Often, Experts Say
The sad truth is that it takes about as long and costs about as much," said Joshua Boger, retired founder and CEO of Cambridge, Mass.-based Vertex Pharmaceuticals Inc., a firm that's dipped its toe into the commercialization arena following approval of protease inhibitor Incivek (telaprevir) in hepatitis C virus. (See BioWorld Today, May 24, 2011.) And these days it's not just enough to get approved -
Commercial Era for Biotech? Plan Early, Often, Experts Say
The sad truth is that it takes about as long and costs about as much," said Joshua Boger, retired founder and CEO of Cambridge, Mass.-based Vertex Pharmaceuticals Inc., a firm that's dipped its toe into the commercialization arena following approval of protease inhibitor Incivek (telaprevir) in hepatitis C virus. (See BioWorld Today, May 24, 2011.) And these days it's not just enough to get approved -
No-Strings Deals Let Rivals Combine Unapproved Drugs
In a Phase II trial of protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052, six of 11 patients broke through, but the others achieved a cure -
Achillion Stock Soars, Offering Raises $52.9M+ for HCV Trials
The company also plans to establish clinical proof-of-concept in the next 12 months for ACH-2684, a pangenotypic protease inhibitor for HCV currently in a Phase I trial, and ACH-2928, an NS5A inhibitor currently being prepared to enter a Phase I trial...In addition, the company said it plans to advance one or more additional HCV NS5A inhibitors to clinical development in the next 12 months, and to initiate clinical testing of a combination of a protease inhibitor and an NS5A inhibitor in 2012 -
Other News To Note
Concert Pharmaceuticals Inc., of Lexington, Mass., achieved a milestone in its alliance with London-based GlaxoSmithKline plc for its HIV protease inhibitor development program, resulting in a $4 million payment to Concert under the 2009 agreement -
HCV Heavyweights Bulk Up for Antiviral Safety Smackdown
Editor When the FDA approved protease inhibitors Incivek (telaprevir) and Victrelis (boceprevir) last month, Vertex Pharmaceuticals Inc...got good results combining a protease inhibitor with an NS5A inhibitor...After all, Vertex already had protease inhibitor Incivek, and it had non-nuc VX-222 thanks to its previous $377 million acquisition of ViroChem Pharma Inc. (See BioWorld Today, March 5, 2009, and June 14, 2011.) Merck, on the other hand, has been playing its cocktail strategy for Victrelis
Category
Current Filters
- xprotease inhibitor
Related Keywords
Categories
- x BioWorld Today (886)
- x BioWorld Insight (249)
- x BioWorld International (95)
- x State of the Industry Report (52)
- x BioWorld Snapshots (17)
- x Bio Perspectives (16)
- x Top 25 Drug Report (10)
- x BioWorld Genomics Review (4)
- x Market-Leading Biotech Drugs (1)